PubRank

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Clinical Trial ID NCT01498978

PubWeight™ 15.74‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01498978

Top papers

Rank Title Journal Year PubWeight™‹?›
1 At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013 1.90
2 CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013 1.71
3 Recent developments in the treatment of renal cell carcinoma. Ther Adv Urol 2013 1.05
4 Molecular pathways and targets in prostate cancer. Oncotarget 2014 1.00
5 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
6 Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol 2013 0.94
7 Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. Curr Opin Oncol 2012 0.92
8 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
9 Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene 2013 0.91
10 Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014 0.90
11 The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development. Cancer Manag Res 2012 0.88
12 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
13 New drugs in prostate cancer. Prostate Int 2016 0.80
14 Immunotherapy for prostate cancer enters its golden age. Clin Med Insights Oncol 2012 0.77
15 Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy. Front Oncol 2020 0.75
16 A Perspective of Immunotherapy for Prostate Cancer. Cancers (Basel) 2016 0.75
17 Immunotherapy in genitourinary malignancies. Curr Opin Urol 2016 0.75
Next 100